CoChat

Cardiovascular Safety, Long‐Term Noncardiovascular Safety, and Efficacy of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta‐Analysis With Trial Sequential Analysis

Open access
Zhang, Xin‐Lin, Zhu, Qing‐Qing, Chen, Yu‐Han, Li, Xue‐Ling, Chen, Fu, Huang, Jian‐An, Xu, Biao · 2018 · Journal of the American Heart Association
Cited by 127

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Background: The cardiovascular and long‐term noncardiovascular safety and efficacy of SGLT 2 (sodium–glucose cotransporter 2) inhibitors have not been well documented. Methods and Results: For cardiovascular outcomes, we performed a meta‐analysis with trial sequential analysis of randomized controlled trials and adjusted observational studies, each with a minimum of 26 weeks and 2000 patient‐years of follow‐up. For long‐term noncardiovascular safety and efficacy outcome analyses, we included only randomized controlled trials with at least 2 years and 1000 patient‐years of follow‐up. Five studies with 351 476 patients were included in cardiovascular outcomes analysis. Meta‐analyses showed that SGLT 2 inhibitors significantly reduced the risks of major adverse cardiac events (hazard ratio [ HR ]: 0.80; 95% confidence interval [ CI ], 0.69–0.92; P =0.002), all‐cause mortality ( HR : 0.67; 95% CI , 0.54–0.84; P <0.001), cardiovascular mortality ( HR : 0.77; 95% CI, 0.60–0.98; P =0.03), nonfatal myocardial infarction ( HR : 0.86; 95% CI , 0.76–0.98; P =0.02), hospitalization for heart failure ( HR : 0.62; 95% CI , 0.55–0.69; P <0.001), and progression of albuminuria ( HR : 0.68; 95% CI , 0.58–0.81; P <0.001). No significant difference in nonfatal stroke was found. Analyses limited to randomized controlled trials showed similar findings. Trial sequential analysis provided firm evidence of a 20% reduction in major adverse cardiac events, all‐cause mortality, and hospitalization for heart failure with SGLT 2 inhibitors, but evidence remains inconclusive for cardiovascular mortality. Nine randomized controlled trials contributed to long‐term noncardiovascular and efficacy analyses. SGLT 2 inhibitors reduced incidence of hypoglycemia and acute kidney injury but increased the risks of urinary tract and genital infections. Conclusions: SGLT 2 inhibitors showed remarkable cardiovascular‐ and renal‐protective effects and good long‐term noncardiovascular safety with sustained efficacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/jaha.117.007165

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 127

Metadata

Authors
Zhang, X., Zhu, Q., Chen, Y., Li, X., Chen, F., Huang, J., & Xu, B.
Venue
Journal of the American Heart Association
Published
2018-01-23
Volume
7
Issue
2
ISSN
2047-9980 (ISSN-L)
OpenAlex
W2786752552
Cited by
127
References
22
FWCI
12.11
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiovascular Safety, Long‐Term Noncardiovascular Safety, and Efficacy of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta‐Analysis With Trial Sequential Analysis. https://app.cochat.ai/papers/10.1161/jaha.117.007165
The paper
Zhang, X., Zhu, Q., Chen, Y., Li, X., Chen, F., Huang, J., & Xu, B. (2018). Cardiovascular Safety, Long‐Term Noncardiovascular Safety, and Efficacy of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta‐Analysis With Trial Sequential Analysis. Journal of the American Heart Association. https://doi.org/10.1161/jaha.117.007165

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.